Upbeat Results For Vertex Pharmaceuticals
Posted on May 07, 2012 at 13:58 PM EDT
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) reported upbeat results from a midstage clinical trial of its cystic fibrosis treatment Kalydeco sending the stock price surging $18.59 to $56.00.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here